EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitHistorischer BeitragOpen Access · CC BY 4.0

Schistosomiasis Chemotherapy, Chemoprevention, and Vaccines: History, Progress, and Priorities

Alaa Oqalaa E Alibrahim, Walaa A Elkholy iD, Mona M El-Derbawy, Noha F Zahran, Athanasios Alexiou iD, Marios Papadakis, Gaber El-Saber Batiha iD

Immunity, Inflammation and Disease · 2024

DOI: 10.1002/iid3.70054 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunity, Inflammation and Disease, 2024. Verfasst von Alaa Oqalaa E Alibrahim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, College of Medicine, Jouf University, Sakaka, Saudi Arabia. Hauptthemen laut MEDLINE: Schistosomiasis, Vaccines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Open access funding enabled and organized by project DEAL. This work was supported by the University of Witten-Herdecke Germany..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Schistosomiasis is a major human disease of public health importance. Freshwater snails serving as intermediary hosts and human interaction with surface water tainted by feces or urine are both necessary components of the transmission cycle. Schistosoma haematobium , Schistosoma mansoni , and Schistosoma japonicum are the primary pathogen species. Over 250 million individuals are infected globally, according to the World Health Organization, causing significant morbidity and an estimated loss of 1.9 million disability‐adjusted life years, a number that is probably underestimated. Immunological protection is slowly built up through complex immunological systems, although innate factors also play a role. Chronic schistosomiasis affects mainly individuals residing in poor rural area. Vaccination is considered as one of the most sustainable options for the control of any pathogen, but schistosomiasis vaccine for humans or animals is not available till now despite the discovery of numerous potentially promising schistosome vaccine antigens.

Objective

To provide an overview of the schistosomiasis chemotherapy, chemoprevention, and vaccines history and progress.

Design

Review article. Data Sources PubMed, ISI Web of Science, Science Direct, and the World Health Organization database.

Conclusion

Favorably praziquantel (PZQ) is a medication with excellent chemopreventive treatment compliance. Due to the extensive usage of PZQ, there is a great deal of debate surrounding the emergence of drug resistance. PZQ is effective against all species of schistosomes, schistosomiasis prevalence has remained largely unaffected, due to reinfection in high transmission areas and growing juvenile worms that were not affected by the drug, even though the need for a schistosomiasis vaccine is even more pressing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchistosomiasisVaccinesHumansAnimalsChemopreventionPraziquantelHistory, 21st CenturySchistosomaHistory, 20th CenturyAnthelmintics

Stichwörter der Autor:innen

chemoprophylaxispraziquantelschistosomiasisvaccines

Substanzen

VaccinesPraziquantelAnthelmintics

Autor:innen und Institutionen

  • Department of Internal Medicine, College of Medicine, Jouf University, Sakaka, Saudi Arabia.
  • Department of Parasitology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
  • Department of Parasitology, Faculty of Medicine for Girls, Al-Azhar University, New Damietta City, Egypt.
  • University Centre for Research & Development, Chandigarh University, Mohali, Punjab, India.
  • Department of Research & Development, Funogen, Athens, Greece.
  • Department of Surgery II, University Hospital Witten-Herdecke, University of Witten-Herdecke, Wuppertal, Germany.

ORCID-Profile: Walaa A Elkholy, Athanasios Alexiou, Gaber El-Saber Batiha

Förderung

  • Open access funding enabled and organized by project DEAL. This work was supported by the University of Witten-Herdecke Germany.

Zitieren

APA

Alibrahim, A. O. E., Elkholy, W. A., El-Derbawy, M. M., Zahran, N. F., Alexiou, A., Papadakis, M., & Batiha, G. E. (2024). Schistosomiasis Chemotherapy, Chemoprevention, and Vaccines: History, Progress, and Priorities. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70054

Vancouver

Alibrahim AOE, Elkholy WA, El-Derbawy MM, Zahran NF, Alexiou A, Papadakis M, et al. Schistosomiasis Chemotherapy, Chemoprevention, and Vaccines: History, Progress, and Priorities. Immunity, Inflammation and Disease. 2024. doi:10.1002/iid3.70054

BibTeX
@article{Alibrahim2024,
  author = {Alibrahim, Alaa Oqalaa E and Elkholy, Walaa A and El-Derbawy, Mona M and Zahran, Noha F and Alexiou, Athanasios and Papadakis, Marios and Batiha, Gaber El-Saber},
  title = {Schistosomiasis Chemotherapy, Chemoprevention, and Vaccines: History, Progress, and Priorities},
  journal = {Immunity, Inflammation and Disease},
  year = {2024},
  doi = {10.1002/iid3.70054}
}
Kostenlos starten →